BiTE® Immunotherapy

Engaging T cells to target tumor cells

BiTE® antibodies are novel recombinant constructs that are designed to utilize the binding properties of variable domains of two monoclonal antibodies.1 One domain is specifically designed to bind to an antigen on the surface of a cancer cell whereas the other is designed to bind to CD3 on the surface of a T cell.1,2 In doing so, BiTE® antibodies aim to leverage the endogenous cytotoxic potential of T cells to target the destruction of malignant cells.1,2 By employing variable domains with the binding specificities against different surface antigens of malignant cells and linking them to a CD3-binding domain, BiTE® antibodies can potentially be engineered to target a wide range of tumors.

References
close
  1. Nagorsen D, Baeuerle PA. Exp Cell Res. 2011;317:1255-1260.
  2. Baeuerle PA, Kufer P, and Bargou R. Curr Opin Mol Ther. 2009;11:22-30.
LEARN MORE ABOUT BiTE® IMMUNOTHERAPY

Designed to Bridge T Cells to Cancer Cells ->